242 related articles for article (PubMed ID: 36769297)
1. Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.
Hakroush S; Tampe B
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769297
[TBL] [Abstract][Full Text] [Related]
2. Implication of platelets and complement C3 as link between innate immunity and tubulointerstitial injury in renal vasculitis with MPO-ANCA seropositivity.
Baier E; Tampe D; Kluge IA; Hakroush S; Tampe B
Front Immunol; 2022; 13():1054457. PubMed ID: 36439156
[TBL] [Abstract][Full Text] [Related]
3. Relevance of Complement C4 Deposits Localized to Distinct Vascular Compartments in ANCA-Associated Renal Vasculitis.
Hakroush S; Kluge IA; Baier E; Tampe D; Tampe B
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430804
[TBL] [Abstract][Full Text] [Related]
4. C-Reactive Protein Levels Are Associated with Complement C4 Deposits and Interstitial Arteritis in ANCA-Associated Renal Vasculitis.
Korsten P; Baier E; Hakroush S; Tampe B
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834488
[TBL] [Abstract][Full Text] [Related]
5. Complement Components C3 and C4 Indicate Vasculitis Manifestations to Distinct Renal Compartments in ANCA-Associated Glomerulonephritis.
Hakroush S; Tampe D; Korsten P; Ströbel P; Tampe B
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205415
[TBL] [Abstract][Full Text] [Related]
6. Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis.
Hakroush S; Tampe D; Ströbel P; Korsten P; Tampe B
Front Immunol; 2021; 12():737708. PubMed ID: 34759920
[TBL] [Abstract][Full Text] [Related]
7. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
Front Immunol; 2021; 12():673912. PubMed ID: 34108971
[TBL] [Abstract][Full Text] [Related]
8. Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.
Singh J; Minz RW; Saikia B; Nada R; Sharma A; Jha S; Anand S; Rathi M; D'Cruz S
Clin Exp Med; 2023 Sep; 23(5):1801-1813. PubMed ID: 36219364
[TBL] [Abstract][Full Text] [Related]
9. Intrarenal synthesis of complement C3 localized to distinct vascular compartments in ANCA-associated renal vasculitis.
Hakroush S; Tampe D; Baier E; Kluge IA; Ströbel P; Tampe B
J Autoimmun; 2022 Dec; 133():102924. PubMed ID: 36209693
[TBL] [Abstract][Full Text] [Related]
10. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
[TBL] [Abstract][Full Text] [Related]
11. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN.
Gou SJ; Yuan J; Wang C; Zhao MH; Chen M
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1884-91. PubMed ID: 24115193
[TBL] [Abstract][Full Text] [Related]
12. Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study.
García L; Pena CE; Maldonado RÁ; Costi C; Mamberti M; Martins E; García MA
Clin Rheumatol; 2019 Oct; 38(10):2819-2824. PubMed ID: 31222573
[TBL] [Abstract][Full Text] [Related]
13. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
14. Complement system activation in ANCA vasculitis: A translational success story?
Kallenberg CG; Heeringa P
Mol Immunol; 2015 Nov; 68(1):53-6. PubMed ID: 26597208
[TBL] [Abstract][Full Text] [Related]
15. Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study.
Yoo BW; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Rheumatol; 2020 Mar; 39(3):831-840. PubMed ID: 31802348
[TBL] [Abstract][Full Text] [Related]
16. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
[TBL] [Abstract][Full Text] [Related]
17. Complement activation prior to symptom onset in myeloperoxidase ANCA-associated vasculitis but not proteinase 3 ANCA associated vasculitis - A Swedish biobank study.
Johansson L; Berglin E; Eriksson O; Mohammad AJ; Dahlqvist J; Rantapää-Dahlqvist S
Scand J Rheumatol; 2022 May; 51(3):214-219. PubMed ID: 35048784
[TBL] [Abstract][Full Text] [Related]
18. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy.
Trivioli G; Vaglio A
Clin Exp Immunol; 2020 Dec; 202(3):403-406. PubMed ID: 32946609
[TBL] [Abstract][Full Text] [Related]
19. The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target.
Mazzariol M; Manenti L; Vaglio A
Curr Opin Rheumatol; 2023 Jan; 35(1):31-36. PubMed ID: 36301247
[TBL] [Abstract][Full Text] [Related]
20. [The expression and clinical significance of neutrophil myeloperoxidase in patients with myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
Liu Y; Peng XC; Xu JN; Zheng MJ; Shuai ZW
Zhonghua Nei Ke Za Zhi; 2022 Sep; 61(9):1016-1022. PubMed ID: 36008294
[No Abstract] [Full Text] [Related]
[Next] [New Search]
